Home » Stocks » ALBO

Albireo Pharma, Inc. (ALBO)

Stock Price: $28.84 USD -1.08 (-3.59%)
Updated May 10, 2021 3:35 PM EDT - Market open
Market Cap 574.10M
Revenue (ttm) 8.73M
Net Income (ttm) -119.88M
Shares Out 19.13M
EPS (ttm) -6.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $28.84
Previous Close $29.91
Change ($) -1.08
Change (%) -3.59%
Day's Open 29.88
Day's Range 28.79 - 30.12
Day's Volume 122,817
52-Week Range 22.08 - 49.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement s...

2 days ago - GlobeNewsWire

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of -33.14% and -25.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–

4 days ago - GlobeNewsWire

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

1 week ago - GlobeNewsWire

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –

3 weeks ago - GlobeNewsWire

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the up...

1 month ago - GlobeNewsWire

– Dosed first patients in Phase 1 study with new product candidate A3907 –

1 month ago - GlobeNewsWire

– Calls to unite global communities affected by rare diseases –

2 months ago - GlobeNewsWire

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –

2 months ago - GlobeNewsWire

BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation ...

2 months ago - GlobeNewsWire

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

2 months ago - GlobeNewsWire

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

2 months ago - GlobeNewsWire

– Company outlining large global rare cholestatic liver disease opportunity –

2 months ago - GlobeNewsWire

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) i...

3 months ago - Seeking Alpha

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocat...

3 months ago - GlobeNewsWire

BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

3 months ago - GlobeNewsWire

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virt...

4 months ago - GlobeNewsWire

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

4 months ago - GlobeNewsWire

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...

4 months ago - GlobeNewsWire

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -

5 months ago - GlobeNewsWire

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

5 months ago - GlobeNewsWire

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -

6 months ago - GlobeNewsWire

- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-

6 months ago - GlobeNewsWire

Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC community to h...

7 months ago - GlobeNewsWire

BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...

7 months ago - GlobeNewsWire

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the prici...

8 months ago - GlobeNewsWire

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it h...

8 months ago - GlobeNewsWire

Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher. The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today appeare...

8 months ago - InvestorPlace

The company reported positive data from a clinical trial.

8 months ago - The Motley Fool

-Highly statistically significant reductions in both pruritus and serum bile acids-

8 months ago - GlobeNewsWire

— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —

8 months ago - GlobeNewsWire

Investors need to pay close attention to Albireo Pharma (ALBO) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

8 months ago - Zacks Investment Research

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒

8 months ago - GlobeNewsWire

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials ——  Enrolled first biliary atresia patients in second odevixibat pivotal study ——  Completed two financing transactions to secure ...

9 months ago - GlobeNewsWire

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron C...

9 months ago - GlobeNewsWire

—  Conference call and webcast to be held at 10:00 a.m. ET — 

9 months ago - GlobeNewsWire

— Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease — — Program expands access to odevixibat ...

9 months ago - GlobeNewsWire

— BOLD is first-ever pivotal trial for biliary atresia —

9 months ago - GlobeNewsWire

Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it wi...

11 months ago - GlobeNewsWire

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — 

11 months ago - GlobeNewsWire

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simo...

1 year ago - GlobeNewsWire

Albireo Pharma like so many small biotech names has been hit hard during the recent COVID-19 market meltdown.

1 year ago - Seeking Alpha

On track to report topline data mid-2020

1 year ago - GlobeNewsWire

About ALBO

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also d... [Read more...]

Industry
Biotechnology
CEO
Ronald Cooper
Employees
90
Stock Exchange
NASDAQ
Ticker Symbol
ALBO
Full Company Profile

Financial Performance

In 2020, Albireo Pharma's revenue was $8.31 million, a decrease of -13.78% compared to the previous year's $9.64 million. Losses were -$107.63 million, 71.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 72.86, which is an increase of 152.68% from the latest price.

Price Target
$72.86
(152.68% upside)
Analyst Consensus: Strong Buy